Citi Trends Reiterates Second Half 2022 Guidance

Guidance The Company is reiterating its guidance for the second half of 2022, as set forth in the second quarter 2022 earnings release. That guidance, which included the impact of the

Guidance

The Company is reiterating its guidance for the second half of 2022, as set forth in the second quarter 2022 earnings release. That guidance, which included the impact of the sale-leaseback of the Roland distribution center, is as follows:

  • Expects low single digit increase in second half total sales compared to first half total sales
  • Expects gross margin to remain in the high 30s to low 40s range for the second half
  • Expects significantly less SG&A expense deleverage in the second half vs. the same period in the prior year as a result of swift expense reduction actions net of incremental lease expense from the sale-leaseback transactions
  • Expects second half operating income to be approximately in line with the second half of 2019
  • Expects year-end cash balance of approximately $85 million to $100 million
Total
0
Shares
Related Posts
Read More

Insmed Provides Business Update At 42nd Annual J.P. Morgan Healthcare Conference; Sees 2024 Global ARIKAYCE Revenues $340M-$360M; Delivers FY23 Revenues Exceeding The Upper End Of Guidance Range With Unaudited Global Net Product Sales Of ~$305.2M

—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million——2024 Global

INSM